Navigation Links
Sentrx Growth Continues with Four New Clients in Second Quarter

Sentrx, a leading provider of drug safety services, gained four new contracts in the second quarter, including a risk evaluation and mitigation strategy (REMS). The company was also awarded a significant contract expansion.

Little Falls, NJ (PRWEB) July 31, 2008 -- Sentrx, a leading provider of [drug safety __title__ drug safety] services, announced today that the company signed four new multi-year contracts in the second quarter of 2008. Combined with wins from the first quarter, Sentrx gained nine clients in the first six months of 2008.

Sentrx pioneered the concept of [drug safety __title__ drug safety] outsourcing for clinical trial safety monitoring, post-marketing safety surveillance, and risk management programs. The multi-year contracts initiated in the second quarter of 2008 include:

  • A risk evaluation and mitigation strategy (REMS) for a biopharmaceutical company
  • Post-marketing safety surveillance with managed safety system hosting for a specialty pharmaceutical company
  • Clinical trial safety monitoring with managed safety system hosting for two biopharmaceutical companies
In addition to the new contracts, Sentrx was awarded a significant contract expansion from an existing large biopharmaceutical client. Sentrx will perform adverse event case processing for additional post-marketed products, doubling the volume of work in 2008.

Sentrx went live with one of the first FDA-required REMS implementations in July, meeting the client's extremely tight timeframe for successful product launch. The Sentrx SafetyTrak® Technology Suite was configured to create a controlled distribution program, ensuring that only registered hospitals order and receive the new drug. Health care professionals in the Sentrx Safety Response Center register hospitals that wish to utilize the treatment in certain post-surgical patients.

"Our second quarter results contain more than one milestone. Besides supporting one of the first REMS, Sentrx will be implementing its first Empirica(tm) Trace instance for a client, making us the only drug safety services provider to offer a choice of [pharmacovigilance __title__ pharmacovigilance] systems," said Joseph Albano, Chief Executive Officer of Sentrx. "Our unique blend of information technology talent, operational excellence and good clinical practices continues to meet the needs of the biopharmaceutical market."

About Sentrx:
Sentrx is a leading provider of technology-enabled solutions and services for global drug safety. Its mission is to help pharmaceutical, biotechnology, medical device, and consumer health companies document the safety profile of their products during clinical development and post-approval, enabling them to minimize risks and maximize benefits. Through its multilingual Safety Response Center, Sentrx delivers a unique combination of highly skilled people, exclusive technology, and best practices in drug safety monitoring. To learn more about Sentrx, please call 1-888-399-8032, extension 261, or click here for a short movie: (
Media Contact:
Jill Notte
Executive Director, Marketing
150 Clove Road
Little Falls, NJ 07424
1-973-812-7575 ext. 261

Read the full story at

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Explosive Growth in Medical Tourism and Rise of Retail Clinics Provide Huge Cost Savings for Patients
2. FGX International Reports Strong Sales and Earnings Growth for the Second Quarter and First Six Months of 2008
3. Hanger Orthopedic Group, Inc. Beats First Call Q2 EPS Estimates by $0.05 on 13% Sales Growth and 57.2% Growth in Net Income
4. VNUS Medical Technologies Reports Second-Quarter 2008 Results: 25% Growth in Net Product Revenues and 38% Growth in Unit Sales
5. Ingenious Med Continues Record Customer Growth and Approaches Key Milestones
6. Southern Home Medicals Encore Medical Staffing Division Poised to Benefit from Major Growth in Nursing Industry
7. Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance
8. Perrigo Company to Present at The Oppenheimer & Co. Inc. 8th Annual Consumer Growth Conference
9. Thermage, Inc. to Present at the Fourth Annual Collins Stewart Growth Conference
10. Cyberonics to Present at Collins Stewart Fourth Annual Growth Conference
11. Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference
Post Your Comments:
Related Image:
Sentrx Growth Continues with Four New Clients in Second Quarter
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... their independence is everything. That is why Hollister Incorporated has launched the VaPro ... offer this next product in the VaPro touch free catheter portfolio,” said Michael ...
(Date:12/1/2015)... ... December 01, 2015 , ... Next IT Healthcare, the leader ... in this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the ... finalist in the category of Digital Solutions for its innovative, industry-leading product, Alme ...
(Date:12/1/2015)... ... December 01, 2015 , ... TCS Healthcare Technologies (TCS), ... population health arenas, is pleased to announce that VIP Care Services, a Caprock ... implemented the ACUITY Complete Care™ Management to back their collaborative catastrophic case management ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , a leader ... leadership since 2008. Gary Bruce, President of PartnerTech North America, currently serves as ... significant amount of time in Sweden since joining PartnerTech based in Malmo, Sweden. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Arash ... Modern Man for 2015. , Angeleno Magazine is a division of Modern ... in 1994, Modern Luxury includes more than 50 magazine titles across 15 major ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , Dec. 1, 2015 During ... in San Francisco, CA , ... to the coronary marketplace. During a satellite symposium, ... Stent Design to Minimize Restenosis", a renowned physician ... available Medinol NIRxcell™ CoCr Coronary Stent System and ...
(Date:12/1/2015)... DUBLIN , Dec. 01, 2015 ... addition of the "Veterinary Equipment and Disposables ... to 2020" report to their offering. ... of the "Veterinary Equipment and Disposables Market ... 2020" report to their offering. --> ...
(Date:12/1/2015)... , Dec. 1, 2015   MabVax Therapeutics Holdings, ... company, announces it has filed an Investigational New Drug ... (FDA) for the Company,s lead fully human antibody product ... acceptance, MabVax plans to initiate the Phase I clinical ... --> The planned Phase I trial ...
Breaking Medicine Technology: